Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nplate REMS Precludes Need For Medicare Coverage Restrictions – Amgen

Executive Summary

Amgen's platelet producer Nplate (romiplostim) does not need coverage restrictions from Medicare to ensure its safe use because it is already the subject of an FDA-mandated Risk Evaluation and Mitigation Strategy, the company told CMS in recent comments

You may also be interested in...



ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress

Erythropoiesis-stimulating agents marketed by Amgen and Johnson & Johnson now confront possible restrictions on use in patients with anemia due to chronic kidney disease, as FDA and CMS gear up for separate advisory panel reviews of emerging safety data on such treatment

ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress

Erythropoiesis-stimulating agents marketed by Amgen and Johnson & Johnson now confront possible restrictions on use in patients with anemia due to chronic kidney disease, as FDA and CMS gear up for separate advisory panel reviews of emerging safety data on such treatment

Amgen’s Nplate Has First Mandatory Patient Registration Under REMS

The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel